The ability of febuxostat on periodontal inflammation and bone loss in rats with periodontitis by regulating nuclear factor-κb

Abstract

We aimed to evaluate the effects of febuxostat on periodontal inflammation and bone loss in rats with periodontitis by regulating nuclear factor-κB (NF-κB). Sixty rats were randomly divided into sham (Group S), periodontitis model (Group P), febuxostat (Group F), minocycline hydrochloride (Group M), NF-κB p65 inhibitor PDTC (Group C), and febuxostat + NF-κB p65 inhibitor PDTC (Group F+C) groups (n=10). The levels of serum tumor necrosis factor-α (TNF-α), interleukin-17 (IL-17), and IL-10 were detected by enzyme-linked immunosorbent assay. The pathological changes in periodontal tissues were detected by hematoxylin-eosin staining, and bone loss was detected using micro-CT. Western blotting was performed to measure the protein expression of NF-κB p65 in periodontal tissues. Group P had significantly higher levels of TNF-α and IL-17 and lower IL-10 levels than those of Group S (P<0.05). Group F had significantly lower levels of serum TNF-α and IL-17 and higher IL-10 levels than those of Group P (P<0.05). The protein expression of NF-κB p65 in the periodontal tissues of Group P was significantly higher than that of Group S, which was lower in Group F and M than that in Group P (P<0.05). Compared with Group P, Group C had significantly lower levels of TNF-α and IL-17, CEJ-AC and protein expression of NF-κB p65, but a higher level of IL-10 (P<0.05), and the trends were the same between Group F+C and Group F (P<0.05). Febuxostat can inhibit periodontal inflammation and reduce alveolar bone loss in rats with periodontitis, probably by inhibiting the activation of NF-κB.

Keywords

• febuxostat
• alveolar bone loss
• periodontitis
• nf-κb